IS SERUM FIBROBLAST GROWTH FACTOR 21 ASSOCIATED WITH THE SEVERITY OR PRESENCE OF CORONARY ARTERY DISEASE?

DA LI JE RAST FIBROBLASTNOG SERUMSKOG FAKTORA 21 POVEZAN SA TEŽINOM ILI PRISUSTVOM KORONARNOG ARTERIJSKOG OBOLJENJA

Gokay Nar1, Sara Cetin Sanlialp2, Rukiye Nar3, Oguz Kılıc4, Mehmet Furkan Ozen1, Guven Gunver5, Cihan İlyas Sevgican1

1Pamukkale University, Faculty of Medicine, Department of Cardiology, Denizli, Turkey
2Servergazi State Hospital, Department of Cardiology, Denizli, Turkey
3Pamukkale University, Faculty of Medicine, Department of Medical Biochemistry, Denizli, Turkey
4Department of Cardiology, Simav Doc Dr. Ismail Karakuyu State Hospital, Kutahya, Turkey
5Department of Biostatistics, Istanbul Medical Faculty, Istanbul, Turkey

Summary

Background: Recent studies have shown that increased circulating concentrations of fibroblast growth factor 21 (FGF21) are associated with obesity, metabolic disorder, and atherosclerosis. However, the relationship between FGF21 and coronary artery disease (CAD) is controversial. This study was planned to investigate the role of FGF21 in CAD development and CAD severity.

Methods: Seventy-eight patients with stable angina pectoris (SAP) (lesion positive) and 40 control patients (lesion negative) with similar cardiovascular risk factors were included in the study. Serum FGF21 levels were measured by ELISA method. CAD severity was evaluated by using SYNTAX and GENSI risk scores.

Results: FGF21 concentrations were found significantly higher in the SAP group than in the control group. [101.18 ± 141.62 vs. 47.93 ± 58.74 pg/mL; p = 0.03], no correlation was found between the SYNTAX (r = 0.146 and p = 0.134) and GENSI (r = 0.211 and p = 0.084) scores with serum FGF21 levels. There was a negative relationship between serum FGF21 and serum HDL-C levels in correlation analysis (r = -0.272; p = 0.026).

Conclusions: The serum FGF21 levels are different between SAP and control patients. FGF21 is a marker for CAD diagnosis, but not for the evaluation of CAD severity.

Keywords: FGF21, stable angina pectoris, coronary artery disease

Address for correspondence:
Rukiye NAR, MD, Associate professor
Pamukkale University, Faculty of Medicine, Department of Medical Biochemistry, Çamlıraflar, Kınıklı Yerleşkesi, Üniversite Cd. No:11, 20160 Pamukkale, Denizli/Turkey
Telephone: 02582966000-5916
e-mail: rukiyenar@hotmail.com
**Introduction**

Cardiovascular diseases (CVDs) are among the most common causes of morbidity and mortality (1). Despite the developments in evidence-based medical treatments and revascularisation strategies, CVD still continues to be a global health problem and leads to a significant burden on the health system (2, 3). Atherosclerosis has been assumed to be a chronic inflammatory process, and the immune system's response to oxidised lipoproteins, in particular, initiates this process (4, 5). Many inflammatory biomarkers, especially cytokines, have been investigated for the prevention and early detection of CVD (2, 6).

Adipose tissue secretes many bioactive adipokines. These adipokines not only affect the metabolism, but also have many effects on the cardiovascular system (3). Fibroblast growth factor (FGF) is a hormone-like structure that plays a role in cell proliferation, hyperplasia, differentiation, and angiogenesis (7). FGF21 is a member of the FGF endocrine subfamily.

High serum FGF21 levels have been shown in obese patients with type 2 diabetes mellitus and metabolic syndrome (10). Although the relationship between FGF21 and CVD has been shown in some studies, its role in the pathophysiology of CAD is still not fully understood (11). We aimed to investigate the role of FGF21 in CAD development and CAD severity in patients with SAP.

**Materials and Method**

**Patient population**

In this cross-sectional case-control study, the patients who underwent coronary angiography with suspicion of CAD at the Pamukkale University Cardiology Department between January 1, 2018 and January 5, 2018 were included. All patients were evaluated in terms of age, gender, history, family history, smoking, presence of comorbidities, and drug use before coronary angiography. The physical examinations were performed. A comprehensive, two-dimensional transthoracic echocardiography (2D-TTE) examination (GE vivid S5) was performed for all patients. The left ventricular ejection fraction (LVEF) was calculated by the bi-planar Simpson method.

Previous acute coronary syndrome (ACS), documented CAD, chronic or inflammatory systemic diseases, autoimmune diseases, malignancies, severe heart valve diseases, a left ventricular ejection fraction <50%, chronic kidney failure (Cockcroft-Gault formula calculated glomerular filtration rate 90 mL/min1.73 m$^2$), haematological disorders, thyroid dysfunctions, pregnancy, and suspicious pericarditis or myocarditis were determined as exclusion criteria. Stable angina pectoris (SAP) was defined as the presence of typical chest pain or equivalent symptoms during exercise and a positive treadmill test or visualisation of ischaemia on stress echocardiography and myocardial perfusion scintigraphy. Patients who did not have any atherosclerotic lesions on coronary angiography were included in the control group. This study was carried out with the approval of the Institutional Review Board of the Pamukkale University Medical Faculty, and informed consent was obtained from all registered patients.

**Blood samples**

Peripheral venous blood samples of the patients were collected after eight to 12 hours of fasting. Fasting serum glucose (FSG), creatinine, triglyceride (TG), total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C) and C-reactive protein (CRP) levels were analysed with the electrochemiluminescence method on a Cobas 702 autoanalyser (Roche Diagnostics GmbH, Mannheim, Germany). The hemogram parameters were analysed with the Mindray BC-6800 system through the electrical impedance method.

**FGF21 level measurement**

Blood samples were centrifuged at 3,000 x g for 10 minutes, and the serum was stored at -80 degrees Celsius (°C) until the analysis. Serum FGF21 concentrations were measured in accordance with the manufacturer’s protocol with a commercial ELISA kit (YLA0238HU, Shanghai YL Biotech Co., Ltd). The concentration range of the assay was 5 to 1,500 pg/mL. The absorbance was measured at 450 nm with a Biotek Elx800 microplate reader (BioTek Instruments Inc., U.S.A.). The data were processed with the Gen5 Data Analysis software (BioTek Instruments Inc., U.S.A.). The variation coefficients within and between experiments were determined as < (8%) and < (12%), respectively.

**Coronary angiography**

Coronary angiography was performed using standard tech-nique (GE Innova 2100) at the Pamukkale University Cardiology Department Selective cine angiographic images of the coronaries were recorded with a digital angiographic system. The significant CAD was defined as narrowing of the vessel lumen diameter > 50%, including the three major coronary arteries and the first branches of the left anterior descending artery or circumflex artery. Diagnostic angiograms were recorded using a digital media viewer and their analysis was randomly performed by two experienced cardiologists, blinded to the study protocol.
Angiographic risk scoring

Atherosclerotic lesion severity was evaluated by using SYNTAX and GENSINI scores. SYNTAX score is a scoring system developed based on the number, location, function and complexity of the coronary lesions, calculated for stenosis diameter of 50% or greater in vessels of 1.5 mm or more in diameter. The final online updated version \[2.11\] was used (www.syntaxscore.com) (12). In the GENSINI scoring system, the lesions were classified as 0–25%, 26–50%, 51–75%, 76–90% according to the degree of angiographic stenosis, and were scored 1,2,4,8,16 and 32 points, respectively. Then the score was multiplied by the coefficient defined according to the localization of the lesion. (Left main coronary artery, 5; proximal segment of left anterior descending (LAD) coronary artery or left circumflex (LCx) artery, 2.5; middle segment of LAD or LCx coronary artery, 1.5; distal segment of LAD and LCx, first diagonal branch, first marginal branch, right coronary artery, posterior descending artery, 1; and intermediate artery and second diagonal and second large marginal branches, 0.5) (13).

Statistical analysis

Statistical analysis were performed on SPSS version 20.0. Normality check for continuous variables were performed by Kolmogorov-Smirnov test and normality assumption was proven for variables and subgroups. Chi-square test was used for categorical variables and independent sample t test was used for continuous variables. Pearson correlation was used to determine relationship between continuous variables. Statistical significance level (alpha) was determined as 0.05.

Results

A total of 118 consecutive patients were enrolled in the study. The baseline demographic, clinical features, laboratory test values and other parameters of the groups are shown in Table I. The patients in the SAP group were significantly older than those in the control group (63.29 ± 10.79 vs 58.88 ± 11.49; p= 0.04), and there were more male patients in the SAP group (74% vs. 58%; p=0.015). The incidences of cardiovascular risk factors, such as hypertension, diabetes and smoking, were similar in both

| Baseline demographics and clinical characteristics | SAP group (lesion +) (n=78) | Control group (lesion -) (n=40) | p value |
|--------------------------------------------------|----------------------------|----------------------------|--------|
| Age (y)                                          | 63.29 ± 10.79             | 58.88 ± 11.49              | 0.04   |
| Males, n (%)                                     | 58 (74%)                  | 21 (53%)                   | 0.015  |
| Hypertension, n (%)                              | 46 (58%)                  | 24 (60%)                   | 0.915  |
| Diabetes Mellitus, n (%)                         | 29 (37%)                  | 12 (30%)                   | 0.438  |
| Smoking, n (%)                                   | 17 (21%)                  | 7 (18%)                    | 0.583  |
| LVEF (%)                                         | 53.45 ± 9.16              | 57.03 ± 6.23               | 0.03   |
| Laboratory data                                  |                            |                            |        |
| FSG (mmol/L)                                     | 7.04 ± 2.73               | 6.64 ± 1.92                | 0.41   |
| Creatinine (mmol/L)                              | 88.4 ± 75.14              | 87.51 ± 27.40              | 0.51   |
| Haemoglobin (g/L)                                | 133.2 ± 19.0              | 135.3 ± 17.3               | 0.56   |
| WBC (×10⁹/L)                                     | 9.34 ± 2.86               | 9.21 ± 2.89                | 0.82   |
| TChol (mmol/L)                                   | 4.62 ± 1.32               | 4.91 ± 1.60                | 0.29   |
| LDL-C (mmol/L)                                   | 2.74 ± 1.15               | 2.79 ± 1.29                | 0.85   |
| HDL-C (mmol/L)                                   | 1.08 ± 0.30               | 1.42 ± 0.89                | <0.00  |
| TG (mmol/L)                                      | 1.79 ± 1.24               | 1.65 ± 0.99                | 0.54   |
| CRP (mg/mL)                                      | 12.9 ± 27.1               | 5.8 ± 5.2                  | 0.12   |
| FGF21 (pg/mL)                                    | 101.18 ± 141.62           | 47.93 ± 58.74              | 0.03   |
| Angiographic data                                 |                            |                            |        |
| SYNTAX score                                     | 23.80 ± 9.53              | 50.01 ± 32.15              |        |
| GENSINI score                                    |                            |                            |        |

Abbreviations: FSG, fasting serum glucose; WBC, white blood cells; TChol, total cholesterol; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; TG, triglycerides; CRP, C-reactive protein; FGF21, fibroblast growth factor 21; LVEF, left ventricular ejection fraction, SAP, Stable angina pectoris.
groups (p > 0.05). LVEF was different between the SAP and control groups (53.45 ± 9.16% vs. 57.03 ± 6.23%, respectively; p = 0.03), and the SAP group had lower serum HDL-C levels (41.57 ± 11.40 vs. 54.90 ± 34.47; p = 0.02).

Serum FGF21 levels of the SAP and control groups were measured as 101.18 ± 141.62 pg/mL and 47.93 ± 58.74 pg/mL, respectively, and showing significantly higher levels in the SAP group (p = 0.03), (Figure 1). Levels of another inflammatory bio-

marker, CRP were similar in both groups (12.9 ± 27.1 vs 5.8 ± 5.2 mg/mL; p = 0.12). There was a significant and negative relationship between serum FGF21 and serum HDL-C levels based on correlation analysis (r = -0.272, p = 0.026), (Table II). The SYNTAX and GENSINI scores of the SAP group were 23.80 ± 9.53 and 50.01 ± 32.15, respectively. However, there was no correlation between the CAD severity risk scores and serum FGF21 levels (r = 0.146, p = 0.234 and r = 0.211 and p = 0.084, respectively), (Figures 2 and 3).

**Discussion**

In this study, we evaluated the role of FGF21 in the diagnosis and severity of CAD. Although, we found a significant difference between the serum FGF21 levels and the diagnosis of CAD in the SAP.
and control groups, there was no correlation between the serum FGF21 levels and the SYNTAX and GENSINI scores.

Several studies have shown that serum FGF21 levels may increase in cardiovascular risk factors such as obesity, hypertension and type 2 diabetes. However, the results of human studies investigating the physiological functions of FGF21 have been inconsistent and contradictory (14, 15). In a study involving 253 Chinese patients, high serum FGF21 levels were an independent risk factor for CAD (8). An et al. (16) found that FGF21 levels increased in diabetic patients and high levels were associated with diabetic complications, including carotid plaques. In another study with 235 patients, the CAD group had higher serum FGF21 compared to non-CAD group (8). Consistent with these studies, we found a statistically significant difference between the serum FGF21 levels of the SAP and control groups. However, Lee et al. (17) did not find significant differences between serum FGF21 levels in patients with or without CAD, using coronary CT angiography to diagnose CAD. The authors explained that this result was due to group matchings in terms of body mass index, age, inflammatory, and lipid markers, and low serum FGF21 levels (17). A study that investigated the role of FGF21 in SAP found higher FGF21 levels (SAP: 323.16 ± 434.66 vs. control: 266.46 ± 417.13 pg/mL; p = 0.039), similar to our study; however, multiple regression analyses showed that FGF21 levels could not be used as a marker for SAP (18). In another study, serum FGF21 levels were found higher in patients with unstable angina pectoris than in the SAP and control group, and there was no difference between serum FGF21 levels in SAP and control subjects unlike to our study (19). This may be due to study design differences, heterogeneities in patients' cardiovascular risk profiles, insulin resistance, drug use, body mass index, visceral fat distribution, and gender distribution.

A few studies have investigated the relationship between CAD severity and FGF21. In a study of 417 patients, the serum FGF21 levels of the patients with CAD and without CAD were similar regardless of the presence of diabetes, and there was no association between the serum FGF21 levels and the severity of CAD defined by the number of stenotic vessels and segments (20). In Park et al. (21) study, no relationship was found between serum FGF21 levels and the severity of CAD determined by SYNTAX scores. In another study, Kim et al. (22) initially observed a significant correlation between serum FGF21 levels and GENSINI and EXTENT scores of 120 patients; however, in the final analysis, they found that there was no relationship between FGF21 levels and the risk scores in diabetic patients (r = 0.332, p = 0.055; and r = 0.296, p = 0.084, respectively). Similar to these studies, we did not find any relationship between serum FGF21 levels and SYNTAX and GENSINI scores.

In this study, we found a negative correlation between FGF21 levels and only HDL-C. No relationship was observed between FGF21 and parameters such as FSG, CRP, non-HDL-C lipid values, creatinine, and LVEF. Indeed, Matuszek et al. (23) confirmed that circulating FGF21 levels had a negative correlation with HDL-C. Similar to our study, Lee et al. (17) failed to demonstrate an association of serum FGF21 levels with FSG and CRP values, and suggested that higher FGF21 levels may be a reflection of hyperinsulinemia rather than high serum glucose levels.

Limitations of the study

The main limitations of our study include its cross-sectional design, small sample, and failure to determine long-term prognoses. The correlation analysis results may also be affected by various uncorrected confounding factors of life. The study was also limited by the collection of blood samples during the stable period before angiography and the inability to measure FGF21 levels simultaneously with the occurrence of chest pain, as acute angina may increase serum FGF21 levels.

Conclusion

Although the serum FGF21 levels were different between patients with and without SAP in this study, there was no significant relationship between angiographic scores of CAD severity and FGF21 levels. One of the strengths of the study is that FGF21 levels, lipid profile, and coronary artery disease severity were evaluated simultaneously. However, larger studies are needed to determine the role of FGF21 in CAD development and progression.

Conflict of interest statement

The authors reported no conflict of interest regarding the publication of this article.
References

1. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2050. PLoS Med 2006; 3: e442.

2. Domouzoglou EM, Naka KK, Vlahos AP, et al. Fibroblast growth factors in cardiovascular disease: The emerging role of FGF21. Am J Physiol Heart Circ Physiol 2015; 309: 1029–38.

3. Jing C, X Su, Lei Q, et al. Circulating level of fibroblast growth factor 21 is independently associated with the risks of unstable angina pectoris. Bioscience Reports (2018) 38 BSR20181099

4. Tedgui A, Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev 2006; 86: 51–81.

5. Weber C, Zernecke A, Libby P. The multifaceted contribution of leukocyte subsets to atherosclerosis: lessons from mouse models. Nat Rev Immunol 2008; 8: 802–15.

6. Crickx E, Saussine A, Vignon-Pennamen MD, et al. Diffuse dermal angiomatosis associated with severe atherosclerosis: Two cases and review of the literature. Clin Exp Dermatol 2015; 40: 521–24.

7. Itoh N, Ornitz DM. Evolution of the FGF and FGFr gene families. Trends Genet 2004; 20: 563–9.

8. Shen Y, Ma X, Zhou J, et al. Additive relationship between serum fibroblast growth factor 21 level and coronary artery disease. Cardiovasc Diabetol 2013; 12: 124. doi: 10.1186/1475-2840-12-124.

9. Li H, Zhang J, Jia W. Fibroblast growth factor 21: A novel metabolic regulator from pharmacology to physiology. Front Med. 2013; 7: 25–30.

10. Bobbert T, Schwarz F, Fischer-Rosinsky A, et al. Fibroblast growth factor 21 predicts the metabolic syndrome and type 2 diabetes in Caucasians. Diabetes Care 2013; 36(1): 145–9.

11. Khalaf MM, Fayez S, Azou T. Serum Fibroblast Growth Factor 21 as a Novel Biomarker in Prediction of Coronary Artery Disease Severity. British Journal of Medicine & Medical Research 2016; 18(9): 1–11.

12. SYNTAX working group. SYNTAX score calculator. Accessed May 20, 2012.

13. Gensini GG. Coronary arteriography: role in myocardial revascularization. Postgrad Med 1978; 63(1): 121–8.

14. Qing L, Yuan Z, Ding D, et al. Association Between Serum Fibroblast Growth Factor 21 and Mortality Among Patients With Coronary Artery Disease. J Clin Endocrinol Metab 2016; 101(12): 4886–94.

15. Vasanthi M, Adole PS, Pandit VR, Vinod KV. Assessment of serum tenascin-C and growth differentiation factor-15 among type 2 diabetes mellitus patients with and without acute coronary syndrome. J Med Biochem 2020; 39(4): 460–6.

16. An SY, Lee MS, Yi SA, et al. Serum fibroblast growth factor 21 was elevated in subjects with type 2 diabetes mellitus and was associated with the presence of carotid artery plaques. Diabetes Res Clin Pract 2012; 96: 196–203.

17. Lee Y, Lim S, Hong ES, et al. Serum FGF21 concentration is associated with hypertriglyceridaemia, hyperinsulinaemia and pericardial fat accumulation, independently of obesity, but not with current coronary artery status. Clinical Endocrinology 2014; 80: 57–64.

18. Matej Stancík. Fibroblast growth factor 21 in prediction of coronary angiography result in stable coronary artery disease patients. Biomed Res DOI: 10.4066/biomedical-research-C7-020.

19. Jing Cheng, Xing Su, Lei Qiao, Chungang Zhai, Wenqiang Chen. Circulating level of fibroblast growth factor 21 is independently associated with the risks of unstable angina pectoris. Biosci Rep 2018 Oct 31; 38(5).

20. Miyazaki Y, Saita E, Kishimoto Y, et al. Low Plasma Levels of Fibroblast Growth Factor-21 in Patients with Peripheral Artery Disease. Journal of atherosclerosis and thrombosis. 2018; (25): 9: 821–8.

21. Park SD, Bae KH, Choi YK et al. Relationship between Circulating FGF21 Concentrations and the Severity of Coronary Artery Damage in Subjects with Cardiovascular Disease. J Lipid Atheroscler 2018; 7(1): 42–9.

22. Kim WJ, Kim SS, Lee HC, et al. Association between serum fibroblast growth factor 21 and coronary artery disease in patients with type 2 diabetes. J Korean Med Sci 2015; 30: 586–90.

23. Matuszek B, Lenart-Lipińska M, Duma D, et al. Evaluation of concentrations of FGF21 a new adipocytokine in type 2 diabetes. Polish Journal of Endocrinology 2010; 61: 50–4.

Received: January 11, 2021
Accepted: March 03, 2021